What is the correct way to manage oral immunotherapy for food allergy during the COVID-19 pandemic?
In patients diagnosed with COVID-19 or cases with suspected SARS-CoV-2 infection, oral immunotherapy dosing should continue as indicated in the dosing plan and in coordination with the treating physician. Oral immunotherapy can be continued in non-infected patients and those who have recovered from COVID-19. In areas with high level of SARS-CoV-2 community transmission, visits to the allergy clinic for oral immunotherapy up-dosing should be postponed. 108,118